MENU
+Compare
ERAS
Stock ticker: NASDAQ
AS OF
Dec 18, 01:52 PM (EDT)
Price
$2.58
Change
-$0.04 (-1.52%)
Capitalization
743.57M

ERAS Erasca Forecast, Technical & Fundamental Analysis

Industry Biotechnology
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for ERAS with price predictions
Dec 17, 2024

Momentum Indicator for ERAS turns negative, indicating new downward trend

ERAS saw its Momentum Indicator move below the 0 level on December 12, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 70 similar instances where the indicator turned negative. In of the 70 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ERAS turned negative on December 11, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

ERAS moved below its 50-day moving average on December 11, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ERAS broke above its upper Bollinger Band on December 02, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for ERAS crossed bullishly above the 50-day moving average on November 29, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in of 178 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 70 cases where ERAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.652) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). ERAS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (260.687).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ERAS is expected to report earnings to rise 19.82% to -13 cents per share on March 20

Erasca ERAS Stock Earnings Reports
Q4'24
Est.
$-0.13
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.11
Q1'24
Missed
by $0.03
Q4'23
Beat
by $0.01
The last earnings report on November 12 showed earnings per share of -10 cents, beating the estimate of -17 cents. With 205.33K shares outstanding, the current market capitalization sits at 743.57M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QNTAX36.20N/A
N/A
Meeder Sector Rotation Adviser
FIKWX12.10-0.01
-0.08%
Fidelity Advisor Asset Manager 30% Z
MDIIX15.48-0.05
-0.32%
iShares MSCI EAFE Intl Idx Inv A
NWJEX139.54-0.60
-0.43%
Nationwide NYSE Arca Tech 100 Idx R6
FAVCX23.92-0.15
-0.62%
Fidelity Advisor Equity Value C

ERAS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+0.38%
XNCR - ERAS
49%
Loosely correlated
+2.12%
KYMR - ERAS
47%
Loosely correlated
-1.76%
BEAM - ERAS
47%
Loosely correlated
-1.21%
ABOS - ERAS
46%
Loosely correlated
-0.51%
PLRX - ERAS
46%
Loosely correlated
+4.74%
More